Sigma Planning Corp Has $1.67 Million Stock Holdings in Ascendis Pharma A/S $ASND

Sigma Planning Corp raised its position in Ascendis Pharma A/S (NASDAQ:ASND) by 52.5% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 7,297 shares of the biotechnology company’s stock after acquiring an additional 2,513 shares during the period. Sigma Planning Corp’s holdings in Ascendis Pharma A/S were worth $1,669,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of ASND. Wellington Management Group LLP raised its holdings in shares of Ascendis Pharma A/S by 95.9% in the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after purchasing an additional 880,836 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Ascendis Pharma A/S by 29.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock worth $218,871,000 after purchasing an additional 232,730 shares during the last quarter. Perceptive Advisors LLC bought a new position in Ascendis Pharma A/S in the second quarter valued at $166,367,000. Vestal Point Capital LP grew its position in Ascendis Pharma A/S by 200.0% in the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after purchasing an additional 400,000 shares in the last quarter. Finally, FIL Ltd increased its stake in Ascendis Pharma A/S by 4.2% in the 4th quarter. FIL Ltd now owns 478,641 shares of the biotechnology company’s stock valued at $102,065,000 after buying an additional 19,301 shares during the last quarter.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 400 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were purchased at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the completion of the purchase, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The disclosure for this sale is available in the SEC filing. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $261.00 on Friday. The stock has a market cap of $16.28 billion, a P/E ratio of 30.10 and a beta of 0.37. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.00 and a quick ratio of 0.72. The company has a fifty day moving average price of $242.89 and a two-hundred day moving average price of $232.02. Ascendis Pharma A/S has a one year low of $160.86 and a one year high of $282.15.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to analyst estimates of $362.47 million. As a group, equities analysts predict that Ascendis Pharma A/S will post 4.63 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ASND shares. Evercore reissued an “outperform” rating and set a $329.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, May 15th. Weiss Ratings raised Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research report on Wednesday. Wall Street Zen lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Saturday. Citigroup began coverage on Ascendis Pharma A/S in a research report on Monday, May 18th. They set a “buy” rating and a $355.00 price target for the company. Finally, Wells Fargo & Company decreased their price target on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of “Buy” and a consensus target price of $295.67.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.